Companies such as Henlius, OriCell, CStone, Gracell and Junshi presented clinical data from their PD-(L)1, cell therapy and other candidates. Henlius impresses with ES-SCLC data, Junshi boasts BTLA-targeted drug and OriCell flaunts GPRC5D-directed CAR-T
Shanghai seems to be where pharma giants are concentrating their efforts to find the next top biotech star. Johnson & Johnson, Boehringer Ingelheim, Roche, Eli Lilly, Merck and AstraZeneca have all launched initiatives to incubate or accelerate Chinese biotech startups.
Elixiron aims to tackle multiple therapeutic areas by looking into pathways to identify targets that hold promise.
Clinical trial researchers in Shanghai not only avoided clinical trial delays but also found ways to initiate new trials during a full-scale lockdown for two months.
Tavotek Biotherapeutics wants to take the lead in multispecific biologic therapeutics to tackle hard-to-treat tumors through its homing concept in early drug discovery and three R&D platforms to drive discovery and development.
At least 11 Chinese drugmakers are known to be developing a COVID-19 oral drug, but experts believe that regulators will need to look at phase III trials differently to approve a long-awaited homegrown COVID-19 pill
China has laid out the pathway to resolve auditing disputes with the U.S. but some bottom lines are drawn, lawyer says
Lawyer says actions of drug originators in the invalidation proceedings will set precedent for patent linkage cases in Chinese courts